Developing first-in-class therapeutics based on cutting-edge science:

ExomeresTM by Exopharm.

 

Therapeutic ExomeresTM

from Stem Cells

Exomeres are biological nanoparticles naturally secreted by stem cells. They are produced using Exopharm’s proprietary LEAP process, which delivers a unique blend of exosomes / vesicles with high-yield.


Exomeres are a cell-free super-drug with the potential to treat a range of conditions such as osteoarthritis, eye disease and fibrosis as a regenerative medicine.


Exomeres carry a rich molecular cargo of nucleic acids, lipids and proteins and are taken up by cells inside the body.


Harnessing natural mechanisms, Exomeres transfer information, energy and cell building materials between cells that promote tissue repair, healing and regeneration

Advancing knowledge in stem-cell therapy is demonstrating that positive medical outcomes can be achieved even without using the therapeutic cells themselves. Instead, the essential therapeutic components are the cell-secreted extracellular vesicles (EVs), including exosomes.


It has become apparent that these EVs alone are sufficient to deliver beneficial effects in models of disease – by efficient delivery of the information, machinery and energy to drive repair programs in damaged tissues. While delivering the therapeutic benefits, Exomeres offer a range of advantages over the use of cells for therapy. Being cell-free, they are easy to transport and deliver to patients around the world. Exomeres also cause less concern over their safety as they are not living cells: they have much more pharmaceutical properties and will not remain in the body for extended periods.


Exomeres – a completely new class of biological therapeutic.

Exopharm is investing in the pharma-grade manufacturing process and preclinical development of Exomeres to enable first clinical trials for the treatment of joint conditions, eye disease and fibrosis.

News

Exopharm Q&A with Bill Kalionis, Head of the Stem Cell Laboratory of the Pregnancy Research Centre at the Royal Womens’ Hospital in Melbourne

The placenta is a phenomenal source of stem cells and regenerative exosomes, and their therapeutic potential extends far beyond conditions of pregnancy, says Bill Kalionis. How did you get into stem cell research? My interest in placental stem cells started quite early in my research career. There’s a classic stem cell type in the placenta called the trophoblast stem cell. I was particularly interested in which genes controlled the important properties of these stem cells. Then, in 2004, mesenchymal stem cells (MSCs) [the major cell type of interest for stem cell therapy] were first isolated from the placenta. It turns out the placenta is a phenomenal source – the sheer number of MSCs...
Read More

Clearing the hurdles with exosomes

Could exosome therapy help athletes recover from injury faster – and help the rest of us by mimicking the whole-body benefits of exercise? Some people don’t get enough physical exercise – but others suffer from too much activity, injury and overtraining. Many sports players are set to benefit from the dawning era of exosome medicine. The regenerative effects of exosome injections may help speed the recovery of many sports-related injuries – as well as injuries picked up at work or around the home – a plethora of publications are beginning to show. Sports injuries come in many forms, from muscle tears to tendon (connective tissue) and cartilage (joint) damage. Sometimes the injury...
Read More

Press Release: Stem Cell Exomere Program announced by RoosterBio and Exopharm

Stem Cell Exomere Program announced by RoosterBio and Exopharm August 08, 2017 released from FREDERICK, MARYLAND and MELBOURNE AUSTRALIA RoosterBio Inc and Exopharm Pty Ltd today announce a formal heads of agreement under which they will work together on a Stem Cell Exomere Program, aimed at bringing high-grade therapeutic extracellular vesicles/exosomes derived from adult stem cells into clinical practice. Exosomes secreted by stem cells are a new class of therapeutic product well suited to be used in regenerative medicine (“RM”) applications, but large scale stem cell manufacturing bottlenecks impede broad clinical use of these natural bioactive nanoparticles. RoosterBio, based...
Read More

Our Team.

Dr. Ian Dixon

CEO

linkedin

Dr. Gregor Lichtfuss

COO

twitter linkedin

Dr. Jim Palmer

Drug Development

linkedin

Melbourne - Australia